

# Preclinical research and development of AD0126 as a selective USP1 inhibitor

Avelos Therapeutics, Inc.



ONCOLOGY	Candidate
Product Type	Small molecules
Indication	BRCA(-) Cancers, HRD(+) Cancers
Target	USP1
MoA(Mechanism of Action)	Inhibition of DNA damage repair mechanisms (translesion synthesis and inter-strand crosslinks)
Competitiveness	Competitors : KSQ4279(Phase 1), ISM-3091(Phase1) Competitiveness - Superior <i>in vitro</i> potency and <i>in vivo</i> efficacy than competitors - No sign of hepatotoxicity - Novel synergistic partner beyond PARP inhibitor
Development Stage	Candidate
Route of Administration	Oral

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*